Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

What Was Tested

This randomized controlled trial paper looks at Lixisenatide.

Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations.

The researchers assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

The researchers randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Lixisenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Lixisenatide could be set against what happens without it.

What Was Measured

The researchers assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.

PubMed files the paper under topics including Acute Coronary Syndrome, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents and Kaplan-Meier Estimate.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Lixisenatide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (The New England journal of medicine), a journal based in United States.

More context: the Lixisenatide compound page.